CN113521094A - 一种治疗湿疹的乳剂软膏及其制备方法 - Google Patents
一种治疗湿疹的乳剂软膏及其制备方法 Download PDFInfo
- Publication number
- CN113521094A CN113521094A CN202110561792.XA CN202110561792A CN113521094A CN 113521094 A CN113521094 A CN 113521094A CN 202110561792 A CN202110561792 A CN 202110561792A CN 113521094 A CN113521094 A CN 113521094A
- Authority
- CN
- China
- Prior art keywords
- pectin
- sodium benzoate
- emulsion ointment
- purified water
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 40
- 239000000839 emulsion Substances 0.000 title claims abstract description 26
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 20
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 51
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000001814 pectin Substances 0.000 claims abstract description 32
- 235000010987 pectin Nutrition 0.000 claims abstract description 32
- 229920001277 pectin Polymers 0.000 claims abstract description 32
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 30
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 30
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000008213 purified water Substances 0.000 claims abstract description 20
- 239000003871 white petrolatum Substances 0.000 claims abstract description 17
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims abstract description 14
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000006071 cream Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 12
- 239000012071 phase Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 244000248349 Citrus limon Species 0.000 claims description 3
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 241000207199 Citrus Species 0.000 claims description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 2
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 2
- 240000006909 Tilia x europaea Species 0.000 claims description 2
- 235000020971 citrus fruits Nutrition 0.000 claims description 2
- 239000004571 lime Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 21
- 241000894006 Bacteria Species 0.000 abstract description 6
- 230000002335 preservative effect Effects 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000002378 acidificating effect Effects 0.000 abstract description 3
- 235000013361 beverage Nutrition 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 235000015094 jam Nutrition 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000006188 syrup Substances 0.000 abstract description 3
- 235000020357 syrup Nutrition 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 239000003862 glucocorticoid Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 2
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229960005040 miconazole nitrate Drugs 0.000 description 2
- 229940053050 neomycin sulfate Drugs 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000008338 calamine lotion Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- YWTYJOPNNQFBPC-UHFFFAOYSA-N imidacloprid Chemical compound [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000011499 joint compound Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗湿疹的乳剂软膏及其制备方法，乳剂软膏按下列质量百分比的原料制成：果胶2‑8％、甘油4‑16％、白凡士林7.76‑31.04％、十八烷醇4‑16％、单甘脂0.16‑0.64％、苯甲酸钠0.08‑0.32％，余量为纯化水。由于加入了苯甲酸钠，其与果胶可以起到协同作用，发明乳剂药膏的PH值处于3.6－3.8。能起到瞬间迅速平衡并调节皮肤表面酸碱环境阻断细菌生长繁殖以形成无菌状态间接消灭细菌.继而产生防治修复的作用。使得治愈时间大大缩短，同时苯甲酸钠易溶于水，防腐作用依靠其未解离分子，防腐最佳PH是2.5‑4.0，在pH4以下的药液中，绝大部分为分子形式，防腐效力较强。而且苯甲酸钠为常用于保藏高酸性水果、果酱、饮料糖浆记忆其他酸性食品，因此，安全性强，对人体没有危害。
Description
技术领域
本发明涉及治疗皮肤疾病领域，具体涉及一种治疗湿疹的乳剂软膏及其制备方法。
背景技术
湿疹是一种皮肤炎症性疾病，湿疹是一种常见的过敏性炎症性皮肤病，湿疹是由多种因素相互作用引起的，其中遗传、环境、饮食、精神压力等被认为是重要的原因。以皮疹多样性，对称分布，剧烈瘙痒，反复发作，易演变成慢性为特征，局部可有红斑，丘疹，水疱，脓疱，糜烂，渗出液，结痂，脱屑，色素沉着，皮肤粗糙，皮肤变厚，有奇痒等。多发于阴囊，大腿内侧，膕窝，肘弯，耳周，乳房等处。
药物现在大多是西药，也有激素成分在里面的，一般不宜长时间使用，可以少量的用，但是时间不宜太久。天然草本类药是治疗湿疹的首选，不含激素，一般不会有太大的依赖性。
当今社会由于生活水平和生活节奏及生活工作学习压力的不断提高，高糖、高热量油炸等食物的大量摄入和过于紧张或忧虑的情绪破坏了肌肤的平衡状态，而且不健康不规律的作息习惯，导致很多内分泌失调促使皮脂分泌过盛，影响表皮细胞的活力，同样是导致过敏湿疹等皮肤疾病的重要诱因之一。局部和全身湿疹，如婴幼儿口水疹，奶水疹，特异性皮炎，和痘痘痤疮及卧床褥疮等都属于一种皮肤病，它严重地影响到生活质量和容貌的美观，而且对容貌的影响不仅限于发病期，还可能因其留下的疤痕而终身遗憾。
目前西医对湿疹尚无特效疗法，多采用对症治疗。以内服抗组胺药物治疗为多，如苯海拉明、非那根、扑尔敏、赛庚啶等，既可单用或联用，还可与镇静药、维生素C等合用。外用药剂型依据临床皮损表现而定，如红肿明显，渗出多者应选溶液冷湿敷，红斑、丘疹时可用洗剂、乳剂、泥膏、油剂等；呈水疱、糜烂者需用油剂；表现为鳞屑、结痂者用软膏；若苔藓样变者多择泥膏、软膏、乳剂、涂膜剂、酊剂及硬膏等。
湿疹的治疗药物主要分为内服和外用两种。内服药物主要有：抗组胺药、抗生素、维生素C和葡萄糖酸钙。一般不常规给予糖皮质激素口服。外用药物需要根据皮损的分期来选择。例如，急性期无渗液或渗出不多者，可用炉甘石洗剂、糖皮质激素乳膏，渗出多的可用3％硼酸溶液冷湿敷；亚急性期可选用糖皮质激素乳膏。慢性期建议外用皮质素软膏、硬膏、乳剂或酊剂。
炎症和感染是湿疹发病的关键因素，针对这一病理机制，可以在医生的指导下选用具有“抗炎、抗真菌、抗细菌感染”三效合一作用的易菲莎曲咪新乳膏。曲咪新乳膏是一种复方制剂，主要有三大成分：醋酸曲安奈德、硝酸咪康唑、硫酸新霉素。醋酸曲安奈德是糖皮质激素类药物，能抗炎、抗过敏、止痒；硝酸咪康唑是广谱抗真菌药，硫酸新霉素是广谱抗菌药。糖皮质激素可以控制炎症症状，抗菌药可以预防细菌和真菌感染，对于已存在和继发的细菌及真菌感染都有治疗作用。这三种成分可一起起到抗炎、抗真菌感染、抗细菌感染的功效，能有效对抗皮炎湿疹。
湿疹是免疫介导的皮肤炎症性反应的疾病，它的内用治疗，往往也是比较重要的。内用治疗，一般用一些抑制炎症的药物，抗感染的，抗过敏的，抗组胺的药物。根据病情的不同，严重程度的不同，会用抗组胺的药物，止痒的药物。外用药，要根据皮损的形态的不同，如果要有渗出，就要采取湿敷的办法；如果没有渗出，只是一些局部的红斑丘疹，我们可能就用一些霜剂膏剂等等。有的时候难免可能会用一些，含有激素的药膏，大家不必担心。如果是合理的使用这些激素的药膏，在合理的使用范围内，它是非常安全的，可以达到很好的疗效。
综上所述可以发现,目前传统中西医尚无特效办法治疗湿疹,一般采用保湿缓解,传统中草药消炎止痒减小很慢很弱,至少一个月或更长,或者单独使用基本没有明显效果；而中西医结合或西医,基本采用外敷外擦含有激素类或抗生素类的药物或霜或膏剂,但都只能作为临时应急用药,一般不能超过一周且遵医嘱,治疗效果一至二周,副作用大, 而且激素抗生素等对人体健康的危害难以估量或保证,病患及家属一般担心程度较高.
发明内容
本发明的目的在于提供一种治疗湿疹的乳剂软膏，以解决现有治疗湿疹时治愈时间长，需要用激素抗生素等对人体健康危害大的技术问题。
为了解决以上技术问题，本发明采取的技术方案是：
一种治疗湿疹的乳剂软膏，其特征在于，按下列质量百分比的原料制成：果胶2-8％、甘油4-16％、白凡士林7.76-31.04％、十八烷醇4-16％、单甘脂0.16-0.64％、苯甲酸钠0.08-0.32％，余量为纯化水，所述乳剂软膏PH值处于3.6－3.8。
所述果胶为从柑橘，柠檬以及青柠的皮中直接提取出来的纯天然果胶产品，无激素，分子量在8-40万之间。
所述果胶3.21-5.63％。
所述果胶3.91-5.00％。
所述果胶3.91％、甘油7.83％、白凡士林15.18％、十八烷醇7.83％、单甘脂0.31％、苯甲酸钠0.16％，纯化水64.78％。
所述果胶4.19％、甘油8.37％、白凡士林16.24％、十八烷醇8.37％、单甘脂0.33％、苯甲酸钠0.17％，纯化水62.33％。
所述果胶4.39％、甘油8.78％、白凡士林17.03％、十八烷醇8.78％、单甘脂0.35％、苯甲酸钠0.18％，纯化水60.49％。
所述果胶4.62％、甘油9.23％、白凡士林17.91％、十八烷醇9.23％、单甘脂0.37％、苯甲酸钠0.18％，纯化水58.46％。
所述果胶4.74％、甘油9.47％、白凡士林18.38％、十八烷醇9.47％、单甘脂0.38％、苯甲酸钠0.19％，纯化水57.37％。
本发明还提供上述治疗湿疹的乳剂软膏的制备方法，其特征在于：包括以下步骤：
(1)制备果胶材料和纯化水相溶液，将制备好的果胶材料和纯化水混合溶解搅拌，转速1000rpm；接着加入甘油，以转速1000rpm搅拌，形成水相溶液；
(2)再将十八烷醇熔化及白凡士林在100-140摄氏度左右熔化，再放入单甘酯继续熔解，以转速500rpm搅拌形成油相；
(3)将油相倒入水相中匀速搅拌，充分乳化后倒入苯甲酸钠继续搅拌后冷却至 50度。
本发明的优异效果：由于加入了苯甲酸钠，其与果胶可以起到协同作用，发明乳剂药膏的PH值处于3.6－3.8，能起到瞬间迅速平衡并调节皮肤表面酸碱环境阻断细菌生长繁殖以形成无菌状态间接消灭细菌.继而产生防治修复的作用。使得治愈时间大大缩短，同时苯甲酸钠易溶于水，防腐作用依靠其未解离分子，防腐最佳PH是 2.5-4.0，在pH4以下的药液中，绝大部分为分子形式，防腐效力较强。而且苯甲酸钠为常用于保藏高酸性水果、果酱、饮料糖浆记忆其他酸性食品，因此，安全性强，对人体没有危害。
具体实施方式
一种乳剂软膏，按下列质量百分比的原料制成：果胶2-8％、甘油4-16％、白凡士林7.76-31.04％、十八烷醇4-16％、单甘脂0.16-0.64％、苯甲酸钠0.08-0.32％，余量为纯化水，乳剂软膏PH值处于3.6－3.8。果胶为从柑橘，柠檬以及青柠的皮中100％直接提纯出来的纯天然果胶产品，分子量在8-40万之间。
下表是实施例1～39不同组分含量的乳剂软膏进行治疗皮肤湿疹试验的试验结果。
上述品乳剂软膏能起到瞬间迅速平衡并调节皮肤表面酸碱环境阻断细菌生长繁殖以形成无菌状态间接消灭细菌.继而产生防治修复的作用。使得治愈时间大大缩短，同时苯甲酸钠易溶于水，防腐作用依靠其未解离分子，防腐最佳PH是2.5-4.0，在pH4以下的药液中，绝大部分为分子形式，防腐效力较强。而且苯甲酸钠为常用于保藏高酸性水果、果酱、饮料糖浆记忆其他酸性食品，因此，安全性强，对人体没有危害。
上述乳剂软膏的制备方法，其特征在于：包括以下步骤：
(1)制备果胶材料和纯化水相溶液，将制备好的果胶材料和纯化水混合溶解搅拌，转速1000rpm；接着加入甘油，以转速1000rpm搅拌，形成水相溶液；
(2)再将十八烷醇熔化及白凡士林在100-140摄氏度左右熔化，再放入单甘酯继续熔解，以转速500rpm搅拌形成油相；
(3)将油相倒入水相中匀速搅拌，充分乳化后倒入苯甲酸钠继续搅拌后冷却至 50度。
通过实施例1～39的乳剂软膏皮肤试验结果表明，实施例15至32区间的，治愈时间最快，效果最佳。
Claims (10)
1.一种治疗湿疹的乳剂软膏，其特征在于，按下列质量百分比的原料制成：果胶2-8％、甘油4-16％、白凡士林7.76-31.04％、十八烷醇4-16％、单甘脂0.16-0.64％、苯甲酸钠0.08-0.32％，余量为纯化水，所述乳剂软膏PH值处于3.6－3.8。
2.根据权利要求1所述的乳剂软膏，其特征在于：所述果胶为从柑橘，柠檬以及青柠的皮中直接提取出来的纯天然果胶产品，分子量在8-40万之间。
3.根据权利要求1或2所述的乳剂软膏，其特征在于：所述果胶3.21-5.63％。
4.根据权利要求3所述的乳剂软膏，其特征在于：所述果胶3.91-5.00％。
5.根据权利要求4所述的乳剂软膏，其特征在于：所述果胶3.91％、甘油7.83％、白凡士林15.18％、十八烷醇7.83％、单甘脂0.31％、苯甲酸钠0.16％，纯化水64.78％。
6.根据权利要求4所述的乳剂软膏乳膏，其特征在于：所述果胶4.19％、甘油8.37％、白凡士林16.24％、十八烷醇8.37％、单甘脂0.33％、苯甲酸钠0.17％，纯化水62.33％。
7.根据权利要求4所述的乳剂软膏，其特征在于：所述果胶4.39％、甘油8.78％、白凡士林17.03％、十八烷醇8.78％、单甘脂0.35％、苯甲酸钠0.18％，纯化水60.49％。
8.根据权利要求4所述的乳剂软膏，其特征在于：所述果胶4.62％、甘油9.23％、白凡士林17.91％、十八烷醇9.23％、单甘脂0.37％、苯甲酸钠0.18％，纯化水58.46％。
9.根据权利要求4所述的乳剂软膏，其特征在于：所述果胶4.74％、甘油9.47％、白凡士林18.38％、十八烷醇9.47％、单甘脂0.38％、苯甲酸钠0.19％，纯化水57.37％。
10.根据权利要求1～9任一所述的乳剂软膏的制备方法，其特征在于：包括以下步骤：
(1)制备果胶材料和纯化水相溶液，将制备好的果胶材料和纯化水混合溶解搅拌，转速1000rpm；接着加入甘油，以转速1000rpm搅拌，形成水相溶液；
(2)再将十八烷醇熔化及白凡士林在100-140摄氏度左右熔化，再放入单甘酯继续熔解，以转速500rpm搅拌形成油相；
(3)将油相倒入水相中匀速搅拌，充分乳化后倒入苯甲酸钠继续搅拌后冷却至50度。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110561792.XA CN113521094A (zh) | 2021-05-23 | 2021-05-23 | 一种治疗湿疹的乳剂软膏及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110561792.XA CN113521094A (zh) | 2021-05-23 | 2021-05-23 | 一种治疗湿疹的乳剂软膏及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113521094A true CN113521094A (zh) | 2021-10-22 |
Family
ID=78124358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110561792.XA Pending CN113521094A (zh) | 2021-05-23 | 2021-05-23 | 一种治疗湿疹的乳剂软膏及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113521094A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225121A (zh) * | 2008-01-25 | 2008-07-23 | 浙江工业大学 | 一种不饱和果胶低聚糖及复合生物防腐剂 |
| CN105497043A (zh) * | 2015-12-18 | 2016-04-20 | 汶上县皮肤病防治站 | 一种治疗皮肤湿疹及湿疹样皮炎的外用药及其制备方法 |
| CN109862787A (zh) * | 2016-08-02 | 2019-06-07 | 弗吉尼亚联邦大学 | 氧化胆固醇硫酸酯(ocs)在治疗炎性皮肤疾病和皮肤损害中的用途 |
| CN110478270A (zh) * | 2019-09-03 | 2019-11-22 | 深圳市腾科系统技术有限公司 | 一种护肤霜及其制备方法 |
| CN111195367A (zh) * | 2018-11-19 | 2020-05-26 | 深圳市腾科系统技术有限公司 | 一种吸收性物品 |
-
2021
- 2021-05-23 CN CN202110561792.XA patent/CN113521094A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101225121A (zh) * | 2008-01-25 | 2008-07-23 | 浙江工业大学 | 一种不饱和果胶低聚糖及复合生物防腐剂 |
| CN105497043A (zh) * | 2015-12-18 | 2016-04-20 | 汶上县皮肤病防治站 | 一种治疗皮肤湿疹及湿疹样皮炎的外用药及其制备方法 |
| CN109862787A (zh) * | 2016-08-02 | 2019-06-07 | 弗吉尼亚联邦大学 | 氧化胆固醇硫酸酯(ocs)在治疗炎性皮肤疾病和皮肤损害中的用途 |
| CN111195367A (zh) * | 2018-11-19 | 2020-05-26 | 深圳市腾科系统技术有限公司 | 一种吸收性物品 |
| CN110478270A (zh) * | 2019-09-03 | 2019-11-22 | 深圳市腾科系统技术有限公司 | 一种护肤霜及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bedi et al. | Herbal therapy in dermatology | |
| US10596148B2 (en) | Topical compositions for treatment of psoriasis | |
| US20080038219A1 (en) | Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof | |
| KR20190095937A (ko) | 설페이트화된 다당류를 포함하는 조성물 | |
| GB2485483A (en) | Botanic skin care compositions for the relief of psoriasis and eczema | |
| Gupta | The efficacy of Euphorbia prostrata in early grades of symptomatic hemorrhoids–a pilot study. | |
| US20240009207A1 (en) | Cannabidiol (cbd) based composition and method for treating pain | |
| JP6298819B2 (ja) | コンパニオン美容組成物 | |
| CN109010174B (zh) | 一种组合物、含有该组合物的湿疹膏 | |
| WO2017036241A1 (zh) | 一种祛痘中药组合物及其制备方法 | |
| CN109431943B (zh) | 一种针对婴幼儿湿疹的修护膏及其制备 | |
| Samarh et al. | Evidence based medical use of aloe vera extracts, short review of literature | |
| WO2022047726A1 (zh) | 一种治疗皮肤病的中药组合物及其制备方法和应用 | |
| WO2009043671A1 (en) | Use of a silybum marianum extract | |
| CN113521094A (zh) | 一种治疗湿疹的乳剂软膏及其制备方法 | |
| Shohrati et al. | Clinical efficacy of topical Avena sativa versus betamethasone in chronic pruritus due to sulfur mustard exposure | |
| US20030072828A1 (en) | Natural therapeutic composition for the treatment of wounds and sores | |
| Nille et al. | Effect of an Ayurveda treatment in palmoplantar psoriasis: A case study | |
| CN116570700B (zh) | 一种具有抑菌、消炎、祛痘功效的中药制剂及其应用 | |
| CN107854542A (zh) | 一种治疗内外痔疮的中药制剂及其制备方法 | |
| Awad et al. | Stasis Dermatitis: Pathophysiology, Current Treatment Paradigms, and the Use of the Flavonoid Diosmin | |
| RU2322987C2 (ru) | Средство для лечения иммунных заболеваний кожи | |
| Bishnoi et al. | Ayurvedic Management of Psoriasis | |
| US20210169823A1 (en) | Topical skin care composition and methods for treating eczema | |
| RU2023444C1 (ru) | Ранозаживляющее средство для местного применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211022 |